SCHEMBL25199754

SCHEMBL25199754

CCOc1cc(/C=C/C(=O)c2ccc(C)cc2C)ccc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.63
CXCL12 P48061 1/20 0.56
PDE4A P27815 1/20 0.56
PDE4B Q07343 1/20 0.56
PDE4C Q08493 1/20 0.56
PDE4D Q08499 1/20 0.56
NFE2L2 Q16236 1/20 0.55
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
MEN1 O00255 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
KMT2A Q03164 1/20 0.52
RELA Q04206 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TRPA1 O75762 1/20 0.52
MAOB P27338 1/20 0.51
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25202909 0.87 TOP2A (0.64) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL32662393 0.87 TOP2A (0.64) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL31233484 0.86 CXCL12 (0.74) CXCL12NFE2L2MEN1NFKB1NFKB2
SCHEMBL15006425 0.86 CXCL12 (0.74) CXCL12NFE2L2MEN1NFKB1NFKB2
SCHEMBL30384277 0.86 CXCL12 (0.74) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL30384133 0.86 CXCL12 (0.74) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL25216640 0.86 CXCL12 (0.74) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL25219819 0.86 CXCL12 (0.74) TOP2ACXCL12PDE4APDE4BPDE4C
SCHEMBL25223568 0.82 NFE2L2 (0.67) NFE2L2MAPTMEN1NFKB1NFKB2
SCHEMBL25223567 0.82 NFE2L2 (0.67) NFE2L2MAPTMEN1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B TOP2A 4354/4885CXCL12 399/4885PDE4A 3506/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 TOP2A 4555/4885CXCL12 287/4885PDE4A 3576/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 TOP2A 4555/4885CXCL12 287/4885PDE4A 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.